We are delighted to announce that Lyomark Pharma has entered into a partnership with Aerogen Pharma. The aim of this strategic partnership is to develop an inhalable surfactant for the treatment of respiratory distress syndrome (RDS) in premature newborns, based on our product Alveofact®. At the same time, we have initiated clinical studies with the new application form, with the first patients already having been recruited.
Details about our partnership and a link with further information on the clinical trials can be found in the following Press release.
Should you have any questions, please do not hesitate to contact us.